New Nanoparticle Immunization Technology Could Protect Against SARS-CoV-2 and Different Coronavirus Variants

The vaccine platform, called a mosaic nanoparticle, is shaped like a cage made up of 60 identical proteins, each of which has a small protein tag that functions like a piece of Velcro. The researchers took fragments of the spike proteins of different coronaviruses (spike proteins play the biggest role in infection) and engineered each to have a protein tag that would bind to those on the cage—the other half of the piece of Velcro. When these viral pieces were mixed together with the nanoparticle cage structure, each virus tag stuck to a tag on the cage, resulting in a nanoparticle presenting spikes representing different coronavirus strains on its surface.

Displaying eight different coronavirus spike fragments (known as receptor-binding domains or RBDs) with this particle platform generated a diverse antibody response, which is an advantage over traditional vaccine methods that present pieces from only a single type of virus. After inoculation, the antibodies subsequently produced by mice were able to react to many different strains of coronavirus. Importantly, the antibodies were reactive to related strains of coronavirus that were not present on the nanoparticle.

This suggests that, by presenting the immune system with multiple different coronavirus variants, the immune system learns to recognize common features of coronaviruses and thus could potentially react to a newly emerging coronavirus - not just a SARS-CoV-2 variant - that might cause another pandemic. Although the team is still studying the mechanism underlying this phenomenon, the results are promising. The next step is to examine whether immunization prevents viral infection and/or infection symptoms in animals making these antibodies.

"If we can show that the immune response induced by our nanoparticle technology indeed protects against illness resulting from infection, then we hope that we could move this technology forward into human clinical trials, though there are a lot of steps that need to happen between now and then," said graduate student Alex Cohen who led the study. "We don't envision that this methodology would replace any existing vaccines, but it's good to have many tools on hand when facing future emerging viral threats."

"Unfortunately SARS-CoV-2 is unlikely to be the last coronavirus to cause a pandemic," said Pamela Björkman, the David Baltimore Professor of Biology and Bioengineering. "Alex's results show that it is possible to raise diverse neutralizing antibody responses, even against coronavirus strains that were not represented on the injected nanoparticle. So we are hopeful that this technology could be used to protect against future animal coronaviruses that cross into humans. In addition, the nanoparticles elicit neutralizing responses against SARS-CoV-2, so it could be possible to use them now to protect against COVID-19 as well as other coronaviruses with pandemic potential."

Related Links:
California Institute of Technology